ADMA Biologics shareholders invited to lead securities fraud class action over alleged financial misrepresentations
Executive summary: Glancy Prongay Wolke & Rotter LLP announced that ADMA Biologics shareholders with losses can lead a securities fraud class action alleging misrepresentations of financial condition and revenue. The filing signals rising litigation risk for biotech and other sector firms, potentially leading to financial settlements and heightened scrutiny of corporate disclosures.
Who is involved: ADMA Biologics Inc. (NASDAQ: ADMA), Glancy Prongay Wolke & Rotter LLP, and affected shareholders seeking lead plaintiff status.
Likely next: The court will set a lead plaintiff deadline; after that, parties may engage in settlement discussions or proceed to class certification proceedings.
On July 29, 2026, Glancy Prongay Wolke & Rotter LLP announced that ADMA Biologics Inc. shareholders who suffered losses may serve as lead plaintiffs in a securities fraud class action alleging misrepresentations about the company's financial condition and revenue. The filing follows a wave of similar suits the same day against First Solar, ZoomInfo Technologies, and Futu Holdings by the same law firm. While the allegations remain unproven, the coordinated filings indicate heightened scrutiny of disclosures across multiple sectors. Outcomes could affect investor confidence and prompt tighter corporate disclosure practices.
Timeline
- — ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
Analysis — what this means
Likely next events
- Lead plaintiff deadline for ADMA Biologics securities class action: August 10, 2026 (per ClaimsFiler alert).
- Lead plaintiff deadline for Planet Fitness (PLNT) securities class action: September 14, 2026 (per Robbins LLP notice).
Sectors affected
- biotechnology
- solar energy
- data analytics
- financial technology
Regulatory implications
- Potential enforcement of SEC Rule 10b-5 regarding misleading statements.
- Possible increased scrutiny under the Securities Exchange Act of 1934, Section 10(b).
- May prompt review of revenue recognition practices under FASB ASC 606 by regulators.
Historical parallels
- 2021 Theranos securities fraud case (SEC charges under Section 10(b) for false blood‑test claims).
- 2020 Nikola Corporation securities class action (alleged misleading statements about battery technology).
- 2020 Luckin Coffee accounting scandal leading to a securities class action and NASDAQ delisting.
Key entities
Sources
- ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit — PR Newswire
Related cases
- Pomerantz Law Firm files class action against ADMA Biologics, with investor deadline of August 10, 2026, amid repeated securities fraud alerts
- ADMA Biologics faces renewed securities litigation pressure as DJS Law Group reactivates investor outreach for August 2026 class action
- ADMA Biologics faces a looming August 10 deadline for investors to assume lead plaintiff role in a securities fraud class action, highlighting ongoing litigation risk for the biotech firm
- Rosen Law Firm reminds ADMA Biologics investors of the August 10 deadline to serve as lead plaintiff in a securities fraud class action
- ADMA Biologics faces an August 10 deadline for lead plaintiff applications in a securities fraud class action
- ADMA Biologics faces a securities class action alleging violations of federal anti‑fraud statutes, raising legal and investor confidence risks